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additional cardiovascular-risk-factors (ASCOT-LLA patients).
ASCOT-BPLA study compared 2 different antihypertensive
strategies (ATE+/-Bendroﬂumethiazide+/-Doxazosin) and AML
(+/-Perindopril+/-Doxazosin) to reduce cardiovascular events
in 19,257 hypertensive patients. AML demonstrated less all
cause mortality than ATE (p = 0.025). A sub-study (ASCOT-
LLA) comparing ATV to Placebo (PCB) in patients with
250 mg/dL was carried out. The ASCOT-LLA was early inter-
rupted because of a signiﬁcant reduction in the primary end-
point in favour of Atorvastatin. A factorial analysis of ASCOT-
LLA (ATV + AML; PBO + AML; ATV + ATE; PBO-ATE)
demonstrated a 53% relative risk reduction of ATV + AML
versus PBO + AML (p < 0.0001); and of 39% for ATV + AML
versus ATV + ATE (p = 0.016). METHODS: Two hypothetical
cohorts of ASCOT-LLA like patients were simulated for a 25
years time horizon under the perspective of the National Health
System, by a Markov model. Spanish costs (€2005) of ATV,
AML, ATE, Peridonpril and Bendroﬂumethiazide were taken
into account. Effects were based on results of the ASCOT 2x2
analysis: ATV + AML versus ATV + ATE. Results are expressed
as incremental cost-effectiveness ratio (ICER) per QALY. Costs
and effectiveness outcomes were discounted at a rate of 3%
and 5% per year, respectively. RESULTS: The basecase analysis
demonstrates that ATV + AML strategy is a more effective
alternative with an acceptable increase in costs: ICER
of ATV + AML was 17.334€ per QALY. CONCLUSION:
Atorvastatin + Amlodipine is a cost-effective strategy when
compared with Atorvastatin + Atenolol for the treatment of
hypertensive patients with no prior history of cardiovascular
disease, normal to mildly elevated cholesterol levels and with
at least 3 additional cardiovascular-risk-factors, being under
the threshold of 30.000€ per QALY usually accepted in our
environment.
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OBJECTIVES: To evaluate clinical and economic beneﬁt of
Drug Eluting Stents (DES) in comparison with Bare-Metal
Stents (BMS) and surgical treatment with coronary artery
bypass graft (CABG) for Sicily Regional Government.
METHODS: Cost-effectiveness analysis was carried out by two
decision models: patients treated with DES vs. BMS. Cost was
carried out from the point of view of the SSR (Servizio Sani-
tario Regionale, Regional Health Service). RESULTS: The use
of DES generated unitary differential savings of €9,003, after
9 months of follow-up, and total differential savings of
€4,114,371. The use of DES on patients destined to BMS gave
average unitary differential savings of €1,075, after 9 months of
follow-up, and average total differential savings of €927,875.
The use of DES instead of BMS and CABG allowed SSR to
make average differential savings of €3,735 per successful case.
A total of €2,476 represent the refund threshold value of DES,
setting to zero the SSR average differential savings for patients
treated with DES who would otherwise have been treated with
BMS. CONCLUSION: Results of the proposed models, tested
with sensitivity analysis, demonstrate the use of DES to be jus-
tiﬁed; moreover, these results could positively inﬂuence the atti-
tude of the SSR towards these new therapeutic strategies, which
are an improvement on standard therapies, both from a clinical
and a ﬁnancial standpoint.
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OBJECTIVES: Familial hypercholesterolemia (FH) is character-
ized by elevated LDL-Cholesterol and premature cardiovascular
disease. To evaluate the efﬁciency of preventive strategies, a
cost-effectiveness model was developed: treatment in real clinical
practice, different atorvastatin dosage in monotherapy 40 mg
(A40) or 80 mg (A80) and atorvastatin combined with Ezetimebe
10 mg (A40 + E10, A80 + E10). METHODS: A Markov model
under National Health System perspective and with a timeframe
of all life expectancy was developed. Spanish life tables (2002)
were modiﬁed with standard mortality rate for FH population
(1.59; IC-95% = 1.07–2.26) to convert the reduction of mortal-
ity into life years gained (LYG). Treatment effectiveness was
transformed in CV mortality reduction by using risk reduction
based on Framingham risk score. Statins, clinical management
and pharmacological costs were taken into account (Spanish
costs €2005). Costs and effectiveness were discounted at a rate of
6% and 3% per year, respectively. RESULTS: 1) Basecase sce-
nario (BS), based on Spanish FH database would represent 1.97
LYG per patient in comparison to no treatment, costs due statins
were €5.321, other management costs (MC) €23.389 and total
costs (TOC) €28710; 2) A40: 2.59 LYG, MC was reduced 4.5%
in comparison to BS; TOC were €30.569; 3)A80: 2.75 LYG,
reduction of MC:6.4%, and TOC: €30.133; 4)A40 + E10: 3.38
LYG, reduction of MC:14.3% and TOC: €36.104; and
5)A80 + E10: 3.62 LYG, reduction of CM: 17.6% and TOC:
€35.317. Management strategies from more to less efﬁcient incre-
mental cost-effectiveness rate (ICER) per LYG in comparison to
BS were: a) A80: €1.821; b) A40: €3.012; and c) A80 + E10:
€4.021; and d) A40 + E10: €5.250. CONCLUSION: Manage-
ment of FH with atorvastatin-based treatment is an efﬁcient
strategy: Atorvastatin 80 mg in monotherapy is the most efﬁ-
cient. If LDL therapeutic goals with Atorvastatin 80 mg are not
achieved, the concomitant use of Ezetimibe can give an addi-
tional effect with an acceptable incremental cost.
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OBJECTIVES: To evaluate the cost-effectiveness of atorvasta-
tin, rosuvastatin, and simvastatin in reducing LDL-cholesterol
(LDL-C) and in treatment of patients with high risk of fatal
cardiovascular disease to meet the European LDL-C target level
of 2.5 mmol/l. METHODS: The efﬁcacy of statins in terms of
mean percent reduction in LDL-C was determined by literature
review and Bayesian random effects meta-analysis. A simula-
tion model was created to evaluate the proportion of patients
treated to the LDL-C target (PTT) level of 2.5 mmol/l. The
uncertainty related to the independent variables was modeled
with Bayesian MCMC-simulation with the use of WinBUGS
software. The measures of cost-effectiveness were calculated by
annual medicine costs per PTT and by incremental cost-
effectiveness ratios (ICERs). The annual medicine costs were
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